Prognostic significance of DAPT scale and D-Dimer level in patients treated with elective PCI

Komarov A.L.; Novikova E.S.; Dobrovol'skiĭ A.B.; Yarovaya E.B.; Guskova E.V.; Samko A.N.; Panchenko E.P.

doi:https://doi.org/10.17116/Cardiobulletin201813239

Komarov A.L.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Novikova E.S.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Dobrovol'skiĭ A.B.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Yarovaya E.B.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation;
Lomonosov Moscow State University, Moscow, Russian Federation

Guskova E.V.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Samko A.N.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Panchenko E.P.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Prognostic significance of DAPT scale and D-Dimer level in patients treated with elective PCI

Authors:

Komarov A.L., Novikova E.S., Dobrovol'skiĭ A.B., Yarovaya E.B., Guskova E.V., Samko A.N., Panchenko E.P.

More about the authors

Journal: Russian Cardiology Bulletin. 2018;13(2): 39‑47

DOI: 10.17116/Cardiobulletin201813239

Read: 2688 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Komarov AL, Novikova ES, Dobrovol'skiĭ AB, Yarovaya EB, Guskova EV, Samko AN, Panchenko EP. Prognostic significance of DAPT scale and D-Dimer level in patients treated with elective PCI. Russian Cardiology Bulletin. 2018;13(2):39‑47. (In Russ.)
https://doi.org/10.17116/Cardiobulletin201813239

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Aim. To study the association between DAPT score, haemostatic factor — D-dimer and prognosis of thrombotic and bleeding events in patients with stable coronary artery disease (CAD), receiving dual antiplatelet therapy (DAPT) after elective percutaneous coronary intervention (PCI). Маterial and methods. The study (2012—2013 years) included 188 patients with stable CAD after elective PCI on DAPT for 6—12 months after the procedure. Individual DAPT score was calculated in patients retrospectively. D-dimer level was assessed by ELISA method the day before PCI. The median of follow-up period was 651 days (min — 23 days and max — 1476 days). Registered thrombotic events: cardiovascular death, acute coronary syndrome, stroke/transient ischemic attack, thrombosis of peripheral arteries, pulmonary embolism. Bleeding events had been characterized by BARC-defined bleeding classification (Bleeding Academic Research consortium, 2011). Results. During the follow-up period incidence rate of thrombotic and bleeding events (BARC 2—5 type) was 15.4% and 12.2%, respectively. Among all patients, 100 (53.2%) patients had a high (≥2) DAPT score, 88 (46.8%) had a low (<2) DAPT score. High (≥2) DAPT score was associated with an increased risk of thrombotic events — OR 3.12 (95% CI 1.1—8.3, p=0.01). D-dimer level had exponential dependence on age among the studied patients. High D-dimer level (≥292 ng/ml for patients <65 years, ≥610 ng/ml for patients ≥65 years) was associated with thrombotic events after DAPT discontinuation — OR 2.6 (95%CI 1.0—6.9, р=0.04).

Keywords:

thrombotic and bleeding events

DAPT score

D-dimer

elective PCI

Authors:

Komarov A.L.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Novikova E.S.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Dobrovol'skiĭ A.B.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Yarovaya E.B.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation;
Lomonosov Moscow State University, Moscow, Russian Federation

Guskova E.V.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Samko A.N.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare, Moscow, Russian Federation

Panchenko E.P.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Close metadata

References:

ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal. 2017;0:1-48. https://doi.org/10.1093/eurheartj/ehx419
ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology. 2016;68(10):1082-1115. https://doi.org/10.1016/j.jacc.2016.03.512
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2011;58(24):44-122.
ESC guidelines on the management of stable coronary artery disease. European Heart Journal. 2013;34:2949-3003. https://doi.org/10.1093/eurheartj/eht296
Kukharchuk VV, Lyakishev AA, Lupanov VP, Panchenko EP, Komarov AL, Ezhov MV, Shiryaev AA, Samko AN, Soboleva GN, Sorokin EV. Diagnosis and treatment of chronic ischemic heart disease. Clinical recomendations [Electronic resource]. Access mode: https://medi.ru/info/12037/ (In Russ.)
Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE. COURAGE. Trial Investigators. Effect of PCI on long-term survival in patients with stable ischemic heart disease. The New England Journal of Medicine. 2015;373:1937-1946.
Komarov AL, Ilyushchenko TA, Shakhmatova OО, Deev AD, Samko AN, Panchenko EP. Comparative efficacy of conservative and invasive treatment of patients with stable form of ischemic heart disease (according to results of five year prospective study). Kardiologiya. 2012;52(8):4-14. (In Russ.)
Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ. DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735-1749. https://doi.org/10.1001/jama.2016.3775
Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L. DAPT Study Investigators. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. Journal of the American College of Cardiology. 2016;67:2492-2502. https://doi.org/10.1016/j.jacc.2016.03.485
Mauri L, Kereiakes DJ, Yeh RW, Yeh RW, Driscoll-Shempp P, Cutlip DE, Gabriel Steg P, Normand S-LT, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, et al. For the DAPT Study Investigators. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. The New England Journal of Medicine. 2014;371:2155-2166.
Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost. 2007;5:1795-1800.
Folsom AR, Gottesman RF, Appiah D, Shahar E, Mosley TH. Plasma d-Dimer and Incident Ischemic Stroke and Coronary Heart Disease The Atherosclerosis Risk in Communities Study. Stroke. 2016;47:18-23. https://doi.org/10.1161/strokeaha.115.011035
Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L. for the AtheroGene Investigators. Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease. The AtheroGene Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2793-2799.
Komarov A, Panchenko E, Dobrovolsky A, Karpov Y, Deev A, Titaeva E, Davletov K, Eshkeeva A, Markova L. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. European Heart Journal. 2002;23(16):1309-1316.
Guskova EV, Panchenko EP, Komarov AA, et al. Residual platelet reactivity to ADP and the bleeding risk in stable CHD patients receiving double antiplatelet therapy for elective percutaneous coronary intervention. Rossiiskii kardiologicheskii zhurnal. 2015;119:35-42. (In Russ.) https://doi.org/10.15829/1560-4071-2015-03-35-42
Novikova ES, Komarov AL, Gus’kova EV, Shakhmatova OO, Deev AD, Dobrovol’skii AB, Samko AN, Panchenko EP. Is the Syntax score sufficient to assess the risk for patients undergoing elective percutaneous coronary interventions? Aterothrombos. 2017;1:80-93. (In Russ.) https://doi.org/10.21518/2307-1109-2017-1-80-93
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747. https://doi.org/10.1161/circulationaha.110.009449
Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, Tumscitz C, Moschovitis A, Windecker S, Valgimigli M. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Annals of Internal Medicine. 2017;167(1):17-25. https://doi.org/10.7326/m16-2389
Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. International Journal of Laboratory Hematology. 2017;39(suppl 1):98-103. https://doi.org/10.1111/ijlh.12665
Byrne A, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M, Oktay S, Jüni P, Kastrati A, Sianos G, Stefanini GG, Wijns W, Windecker S. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. European Heart Journal. 2015;36(38):2608-2620. https://doi.org/10.1093/eurheartj/ehv203
Urban P, Abizaid A, Banning A, Bartorelli AL, Baux AC, Džavík V, Ellis S, Gao R, Holmes D, Jeong MH, Legrand V, Neumann FJ, Nyakern M, Spaulding C, Worthley S. e-SELECT Investigators. Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry. Journal of the American College of Cardiology. 2011;57:1445-1454. https://doi.org/10.1016/j.jacc.2010.11.028
Naidu SS, Polin GM, Selzer F. Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Different Time Periods. The American Journal of Cardiology. 2006;98:447-452. https://doi.org/10.1016/j.amjcard.2006.03.021
Lau J, Alcock R, Cherry J. Application of the DAPT score to a contemporary Percutaneous Coronary Intervention cohort. Journal of the American College of Cardiology. 2016;6818(suppl B). https://doi.org/10.1016/j.jacc.2016.09.263
Tabassome Simon, Etienne Puymirat, Francois Schiele. Discriminant value of the DAPT score to predict long-term ischemic and bleeding events in the real world population of stented patients in the fast-MI 2005 cohort. Journal of the American College of Cardiology. 2017;69(11). https://doi.org/10.1016/s0735-1097(17)33498-8
Yusuke Yoshikawa, Hiroki Shiomi, Hirotoshi Watanabe. Application of DAPT score to predict ischemic and bleeding events in japanese patients undergoing drug-eluting stent implantation: an observation from a pooled cohort of the credo-kyoto cohort-2, reset, and next trials. Journal of the American College of Cardiology. 2017;69(11). https://doi.org/10.1016/s0735-1097(17)33648-3
Matteau A, Yeh RW, Camenzind E, Steg PG, Wijns W, Mills J, Gershlick A, de Belder M, Ducrocq G, Mauri L. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. The American Journal of Cardiology. 2015;116(5):686-693. https://doi.org/10.1016/j.amjcard.2015.05.036
Tzoulaki I, Murray GD, Price JF. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. The American Journal of Epidemiology. 2006;163(4):334-341.
Gus’kova EV. Faktory, opredelyayushchie bezopasnost’ dvoinoi antitrombotsitarnoi terapii posle planovykh chreskozhnykh koronarnykh vmeshatel’stv: Dis... kand. med. nauk. M.: 11-i FORMAT; 2016. (In Russ.)
ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2014;35(43):3033-3073. https://doi.org/10.1093/eurheartj/ehu283